Alaunos Therapeutics (TCRT) Registration Filing summary

Company overview and business model

• Focus shifted to developing a preclinical small molecule oral obesity program with a non-hormonal mechanism, aiming for a differentiated profile versus current obesity drugs.

• Previously operated as a clinical-stage oncology cell therapy company, but wound down TCR-T programs in 2023 due to costs and financing challenges.

• Exploring strategic alternatives, including asset sales, partnerships, or mergers, to maximize stockholder value.

Financial performance and metrics

• No product revenue generated to date; significant net losses since inception.

• Net loss of $2.1 million for the six months ended June 30, 2025; accumulated deficit of $922.6 million since 2003.

• R&D expenses for cancer programs declined from $11.7 million (first half 2023) to $0.3 million (first half 2025) after strategic reprioritization.

• Stockholders' equity was $3.66 million as of June 30, 2025, after previously falling below Nasdaq's $2.5 million minimum.

Use of proceeds and capital allocation

• May receive up to $25 million from equity sales to Mast Hill Fund, plus up to $319,600 from warrant exercises.

• Proceeds intended for working capital, general corporate purposes, sales and marketing, product development, and potential acquisitions or investments.

• Management retains broad discretion over allocation of proceeds; actual uses may vary based on business needs.